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Abstract: Despite the risks associated with hypnotics and their recent increased use in Saudi Arabia,
there are no specific national guidelines for using these medicines to treat insomnia nor are there any
data on how these medicines are currently prescribed. There is the potential, however, that some
physicians might be adhering to the United States guidelines. The current audit study was aimed to
assess the current practice in treating insomnia with hypnotics in Saudi Arabia, and to evaluate its
agreement with the US guidelines. The audit was conducted using data collected between April 2012
and March 2017 at King Fahad Central Hospital (KFCH; Jazan), of patients who were either prescribed
benzodiazepines (BZDs) or Z-drugs or diagnosed with insomnia. The audit criteria followed two
US guidelines for the management of insomnia in adults. Data included documented diagnosis,
use of CBT-I (Cognitive Behavioral Therapy for Insomnia), use of BZDs and Z-drugs including
treatment regimen, and whether physicians prescribed anti-histamines for insomnia. The data
were analyzed using STATA 14 after transcription to a MS XL file. Of the 504 records reviewed,
379 patients (75%) were prescribed BZDs or Z-drugs; only 182 (48%) of them had clearly documented
indications for their use. Three hundred and seven patients (60%) were diagnosed with insomnia;
none of them received CBT-I as initial treatment. No patients on long-term use of hypnotics were
reviewed by their physicians after they began using the medication. More than 43% of patients were
prescribed anti-histamines for insomnia. No records met all (or even six) of the seven criteria. KFCH
physicians do not follow US guidelines. Therefore, the Ministry of Health (MOH) should improve its
administrative systems including documentation, and instead of using international guidelines that
are seldom followed, physicians should be trained in prescribing hypnotics and national guidelines
need to be developed.
Keywords: clinical practice; hypnotics; benzodiazepines; z-drugs; audit; primary insomnia; tertiary
hospital; Saudi Arabia
1. Introduction
Studies show that while benzodiazepines (BZDs) and Z-drugs (eszopiclone, zolpidem and
zaleplon) are associated with a high risk of patient misuse, and cause addiction, dependence, falls,
accidents, cognitive impairment and withdrawal symptoms, the therapeutic benefits outweigh the
disadvantages if the drugs are prescribed appropriately [1,2]. In the United States, the United Kingdom,
and other countries, the known risks have led to clinical guidelines to help physicians prescribe the
medicines safely, and to minimize the risk of addiction [3–7].
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While these guidelines contain attributes specific to the countries where they are applied, there
are recommendations common to all, among which is the importance of using the smallest dosage
possible to induce a therapeutic effect. Other shared recommendations include the preferred length of
the prescription (2–4 weeks), the consideration of non-pharmacological treatments prior to hypnotic
prescription, using drugs with the lowest cost, the recommendation that new medicines be withheld if
the prescribed hypnotics are unsuccessful (except when the patient experiences adverse effects), and
that prescriptions must include a withdrawal plan [3,6–8].
BZDs and Z-drugs have severe adverse effects if taken for longer than the recommended treatment
period (more than 4 weeks) [3]. Despite this, the effectiveness of these medicines to treat insomnia
justifies their administration if they are used appropriately and for short durations. The national
guidelines for insomnia management in the US and UK begin with sleep hygiene, non-pharmacological
remedies such as cognitive behavioural therapy for insomnia (CBT-I), and only after these treatments
have been attempted, is the short-term use of hypnotic medicines considered for patients with severe
insomnia [3,6,7]. Even when the guidelines are followed, the literature shows that patient misuse
of BZDs and Z-drugs still occurs [9–12]. In addition, prescribing hypnotics for long-term use might
indicate that physicians do not adhere to the guidelines.
Some audit studies have been conducted on the use of hypnotics in different regions across the
world. One such study used 308 medical records to assess the use of hypnotics to manage insomnia,
and compared the results to the National Institute of Clinical Excellence (NICE) guidelines. The study
found that a non-pharmacological treatment was provided to only 25% of patients, whereas 33%
were prescribed hypnotics for less than one year and 10% were prescribed these medicines for more
than 10 years [11]. Another prospective audit study was conducted in Ireland to assess the level of
prescription compliance using the main components for Z-drugs and BZD prescribing guidelines. The
study over four weeks involved 81 community pharmacies and reported that less than one-fifth of the
prescriptions were fully compliant with the assessment criteria; many of the prescriptions also had
discrepancies [12].
Although pulmonologists in Saudi Arabia began sleep studies in the early 1990s [13], the Saudi
Commission for Health Specialties (SCHS), which authorizes all health specialty professionals in Saudi
Arabia, did not recognize sleep medicine as an independent specialty until 2012 [14]. For this reason,
there is insufficient data concerning insomnia treatments in the Kingdom of Saudi Arabia (KSA),
including how BZDs and Z-drugs are used in the Kingdom. Even though these types of medicines are
restricted in Saudi Arabia and only specialists and consultants are authorized to prescribe them, most
of the literature considers BZD usage for psychiatric disorders only [15–17]. Thus, further studies are
necessary to investigate the use of these medicines for insomnia in the KSA. The motivation to conduct
this audit study, in addition to the aforementioned problems, included the absence of well-developed
clinical guidelines for the use of BZDs and Z-drugs to manage primary insomnia in the KSA. Thus,
this audit study reports data gathered on the current clinical practice in a major regional Ministry of
Health (MOH) referral hospital (King Fahad Central Hospital (KFCH) in Jazan) where hypnotics are
used to treat insomnia.
This audit aims were to assess the current practice to treat insomnia with hypnotics in Saudi
Arabia, and to evaluate its agreement with the US guidelines. There are two such guidelines, one
from the American Academy of Sleep Medicine (AASM) and the other from the American College of
Physicians (ACP) [3,7]. In this audit study, we attempt to answer the following questions in the absence
of national clinical guidelines: what is the current clinical practice when prescribing hypnotics for
patients with insomnia in Saudi Arabia, and how different is the current practice from the American
guidelines? The US guidelines were used because there are no country-specific guidelines for the
treatment of insomnia in Saudi Arabia, and most Saudi physicians were taught using the American
system at medical schools. In addition, the Saudi MOH and other departments that provide most
medical services in Saudi Arabia often adopt US guidelines [18] because they are believed to be the
best medical practice [19].
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After the research criteria were developed, a systematic review of randomized controlled trials
(RCT) to elucidate the usefulness of pharmacological agents to treat chronic sleep disorders from
the AASM was published [4]. The review focused only on treatment rather than other management
criteria, and it was recommended that treatments should follow the 2008 guidelines of the AASM [4].
This did not affect the previously developed criteria. The present paper reports on the first four steps
of the traditional audit: it identifies the problem, develops the tool to measure the outcome, collects
data and compares the findings with established standards, and suggests changes [20].
2. Materials and Methods
The study was conducted at KFCH, a 500-bed tertiary hospital in Jazan that serves 20 other
hospitals in the region with approximately 1.5 million inhabitants. A tertiary hospital is defined as
a facility that provides specialized care using highly advanced and complex procedures performed
by medical specialists [21]. These facilities usually deal with referrals from primary and secondary
care facilities. Thus, the audit was conducted in this facility because in Saudi Arabia these types of
medication cannot be prescribed in primary care since prescription of controlled drugs is limited to
secondary and tertiary care centers.
Since 2009, KFCH has used MedicaPlus, an electronic information system which also permits
electronic prescriptions. MedicaPlus connects the hospital’s various departments. Information can
be retrieved using patient name, ID numbers, diagnosis, and prescribed medicines. Audit criteria
were developed from the AASM and ACP clinical guidelines [3,7] as they are the two published
guidelines most often followed; this means the criteria have already been validated. The data collection
tool was also verified by an expert in clinical audits (D.G.), as well as the researcher’s supervisor,
prior to the performance of the study. All standards and consensus recommendations related to
the use of BZDs or Z-drugs and/or the management of primary insomnia from the guidelines were
incorporated into the criteria to develop a data collection tool (Table 1) to be applied in the KSA.
The criteria were devised by the authors to indicate the best practice for insomnia treatment. Standards
and consensus recommendations that were not related to the management of primary insomnia,
for example diagnosing insomnia, were excluded. Thus, the data collection audit tool was designed to
retrieve patients who had been:
• not only prescribed BZDs or Z-drugs but also had clear documentation of their use;
• given CBT-I as the initial treatment (documented);
• prescribed these drugs when physicians decided to use pharmacological treatment;
• initially prescribed the lowest licensed dosage of BZDs or Z-drugs;
• prescribed the drugs specifically for the maximum recommended duration (4–5 weeks);
• on long-term use of the medicines and were reviewed by their doctors every few weeks or on
a monthly basis, and then every 6 months (documented).
During the study period of March–May 2017 at KFCH, the first author (A.D.) performed an
electronic search of the medical records using the terms insomnia and/or the generic and trade names
of BZDs and Z-drugs, with the advice of the hospital pharmacy and quality management departments,
to identify patients. After eliminating duplicates, 771 records met the inclusion criteria of adult patients
(aged 18 years and over) with insomnia who were prescribed drugs as a treatment, or their diagnosis
was documented, during the period from April 2012 to March 2017. Data were collected from medical
records of patients admitted to different wards, as well as for outpatients. Patients were excluded
if they were prescribed any of these medicines for other indications such as an add-on therapy for
epilepsy, dementia, psychosis or other psychiatric disorders; as part of substance withdrawal treatment
(e.g., methadone or alcohol); for terminal illness; or if patients were admitted to the intensive care
unit (ICU). After applying the exclusion criteria, 504 patients were deemed appropriate for the data
collection process.
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Table 1. Data collection tool.
Patient Number
Prescribing physicians’ numbers
Patients who were prescribed these medications had clearly documented indications for use (YES/NO)
Patients received CBT-I as the initial treatment (documented) (YES/NO)
Patients were prescribed BZDs or Z-drugs if pharmacological treatments were considered (YES/NO)
Patients were initially prescribed the lowest licensed dosage (for adults or elderly) of BZDs or Z-drugs
(YES/NO)
Patients were prescribed BZDs or Z-drugs for 4–5 weeks (YES/NO)
Patients on long-term use of medicines were reviewed by their doctors every few weeks or monthly and then
every 6 months (Documented) (YES/NO)
To treat chronic insomnia, anti-histamine or anti-histamine/ analgesic medicines were used (YES/NO)
As this study is one of three studies of a PhD research project at the University of Reading in the
UK, the University of Reading Ethics Committee (UREC) provided guidance and approved the study
number (17/15), on 8 March 2017. On 19 March 2017, similar guidance and approval were given by
the Research Ethics Committee of the General Directorate of Health Affairs (Jazan), Ministry of Health,
Saudi Arabia. Permission to access the data was obtained from the Hospital Director and coordinated
with the medical records department.
Before data collection began, the researcher received suitable training from the medical records
technicians on how to use medical records and collect the required data at the hospital. The data
collection tool was piloted using 10 medical records to ensure that all relevant information could
be gathered. Obtained data were anonymized, and the last four digits of each patient’s hospital ID
substituted with identification letters. Names, addresses or other personal information were not
collected. In addition, the prescribers’ identities were anonymized using a unique identifier number.
Information on KFCH physicians’ current practices was gathered from the medical records and entered
into the data collection tool for comparison with the audit criteria. No names, addresses and other
personal information were collected.
Data extracted from the medical records were coded by one of the authors (A.D.) as “YES or NO”
options to indicate whether or not the criterion had been met. Data were transferred from the data
collection sheet (MS Word) into an MS XL file and then entered into STATA 14 for analysis [22]. All
variables (i.e., criteria) had a “YES/NO” response. These responses were recoded for convenience
as follows: all “YES” responses were recoded as 1, and all “NO” responses were recoded as null.
Tabulate (tab) and summarize (sum) commands provided the descriptive statistics in STATA and
showed the number (and percentage) of records that met each criterion. The reliability of the findings
was addressed by using a structured and documented process for data collection and analysis. The
validity was addressed by the process of inspecting the data collected at the different stages. Figure 1
presents a summary of the study process.
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3. Results
The results were computed based on 504 medical records of patients treated for insomnia using
BZDs or Z-drugs or any other medication. Of the 504 reco ds which met the inclusion criteria:
• 75% (379) of patients were prescribed BZDs or Z-drugs, and of these, 48% (182) had clearly
documented indications for their use.
• 61% (307) of patients received some form of medication for insomnia; none were offered or
received CBT-I as a first-line treatment; 59% (182) used BZDs or Z-drugs as first treatment, of
which 65% (118) began with the lowest recommended dose; 51% (93) of all prescriptions complied
with the recommended duration.
• After being prescribed BZDs or Z-drugs and beginning medication use, no patient was reviewed
by the physician for the effects of long-term use.
• 4 % (134) of patients ere given anti-histamines or anti-histamine analgesics (combination of
paracetamol and diphenhydramine) for inso nia.
In addition, antipsychotic medicines such as quetiapine and olanzapine or antidepressants such
as mirtazapine and doxepin were prescribed for some patients as first line pharmacological treatment.
Table 2 shows that physicians in KFCH do not follow the current US guidelines for insomnia treatment.
Table 2. Number and percentage of the responses to the audit criteria.
Indicators Records Count Yes Percentage %
Patients who received BZDs or Z-drugs had clearly documented
indications for use 379 182 48
Patients received CBT-I as the initial treatment (documented) 307 0 0
Patients were prescribed BZDs or Z-drugs if pharmacological
treatments were considered 307 182 59
Patients were initially prescribed the lowest licensed dosage of
prescribed BZDs or Z-drugs 182 118 65
P tients were prescribed BZDs or Z-drugs fo 4-5 weeks 182 93 51
Patients on long-term use of medicines were reviewed by their
doctors every few weeks or monthly, and then every 6 months 89 0 0
To treat chronic insomnia, anti-histamine or anti-histamine
analgesic medicines were sed 307 134 44
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The most important points are that CBT-I was not used as an initial treatment, BZDs and Z-drugs
were prescribed without documented indications for use, patients were not reviewed by their doctors
once they started using the medicines, and physicians used non-recommended medicines such as
anti-histamines to treat insomnia. Table 3 shows how many criteria were followed based on each
individual record.
Table 3. Criteria followed by individual records.
Number of Criteria Met Count Percentage (%)
Met 0 criteria 13 4.2
Met 1 criterion 105 34.2
Met any 2 criteria 47 15.3
Met any 3 criteria 69 22.5
Met any 4 criteria 62 20.2
Met any 5 criteria 11 3.6
Total 307 100
It should be noted that none of the records met all the criteria or even six of them, and only
11 (3.6%) met five criteria. Approximately one-third of the records of patients diagnosed with insomnia
met only one criterion. This means that physicians at KFCH are either unaware of current guidelines
or are unwilling to comply with them when treating patients with insomnia.
4. Discussion
To the best of our knowledge, this audit study is the first to assess the practice of prescribing BZD
and Z-drugs in the KSA. The current results indicate that physicians at KFCH do not follow the US
guidelines for prescribing BZD or Z-drugs for insomnia, nor do they comply with all audit criteria
developed from these guidelines. After excluding the first and sixth criteria (using CBT-I as initial
therapy and reviewing patients taking the drugs for long periods), only 60 medical records met the
remaining five audit criteria (less than one-fifth of cases). Additionally, 109 medical records of the
307 patients who were diagnosed with insomnia failed to meet even one of the six criteria. Therefore,
physicians treated one-third of patients with primary insomnia without reference to the guidelines.
This suggests that many KFCH physicians are either unaware, unwilling or unable to comply with
international guidelines.
Furthermore, documented indications of use were found in less than half of patients prescribed
the drugs under investigation. This might be due to an inadequate prescribing system, physicians’
busy schedules, or because they are not aware of the guidelines or the value of recording indications
for drug use. Alternatively, physicians might not believe that the symptoms/indications warrant
documentation. However, it is important for other physicians to have a complete patient history of
drug-use to ensure that they can undertake a thorough diagnosis of the patient before initiating or
continuing treatment [23].
The Clinical Guidelines for the Evaluation and Management of Chronic Insomnia in Adults [3]
recommend that BZDs and Z-drugs should be prescribed only after accurate diagnosis and when
symptoms are associated with daily dysfunction [3]. Telephone interviews in the UK, Germany, Italy,
and Portugal have found that chronic insomnia is related to anxiety and depression [24]. For this
reason, a clear indication should be documented to improve physician-to-physician communication
and help physicians to consider the underlying issues associated with chronic insomnia. To avoid
prescription duplication, physicians need to document indications for the use of BZDs and Z-drugs,
which would assist other professionals with patient treatments. Furthermore, poor documentation can
lead to severe consequences such as misdiagnosis, lack of communication between physicians, and/or
inappropriate prescribing of medications [25].
Our study findings show that compared to US guidelines, BZDs and Z-drugs were prescribed
inappropriately for the majority of patients at KFCH. The audit also revealed that no patient received
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CBT-I as a preliminary treatment step, as recommended by the US guidelines [3,7]. Although the
evidence shows that CBT-I has the same effect in the management of insomnia as pharmacological
treatments for short periods, is superior for long periods, and is preferred by patients [26], this was
clearly not the case at KFCH where patients did not receive CBT-I.
The guidelines from the AASM state that combined treatments (CBT-I and pharmacological)
are required and even preferred when the availability of other treatments, the occurrence of side
effects, dependence on past treatment, and patient preference are considered [3]. This audit found that
pharmacological treatment was the only documented method of treatment administered to patients
with insomnia at KFCH. This discrepancy might be due to a belief that CBT-I is not effective or worth
documenting, or due to the physicians’ busy schedule and the short consultation time. The lack of
a referral process or shortage of psychologists with expertise in CBT-I might also explain its non-use.
According to Saudi Arabia–World Health Organization (2014), in the Kingdom (population: 32 million)
only 1.38 psychologists exists per 100,000 of the population [27].
The results also indicated that physicians at KFCH did not prescribe BZDs or Z-drugs for two-fifths
of patients diagnosed with insomnia. The audit showed that physicians prescribed antipsychotic
medicines such as quetiapine and olanzapine or antidepressants such as mirtazapine and doxepin.
In addition, many prescribed anti-histamines or anti-histamine analgesics, either alone or with other
medicines, were given to more than 43% of patients, even though the AASM recommends neither
for chronic insomnia [3]. Although the KSA’s Ministry of Health Drug List recommends the use of
temazepam and nitrazepam [28], physicians at KFCH do not prescribe these medications. These
findings confirm that many physicians at KFCH do not comply with the US guidelines concerning
the use of BZDs or Z-drugs as an initial treatment for insomnia. This might be due to unawareness or
a lack of concern regarding side effects.
More worryingly, over one-third of patients were not prescribed the lowest effective dose of BZDs
or Z-drugs, and most elderly patients were prescribed the same dose as younger adults. This ignores
the US guidelines that state that older patients should receive half the standard adult dose and that
doses should be limited to prevent addiction issues and severe side-effects [3]. Older adults are more
susceptible to BZD or Z-drug toxicity, which might result in permanent sedation, falls, coma and/or
death due to overdose [29]. High dosage prescriptions of BZDs or Z-drugs in KFCH suggest that
elderly patients are vulnerable to poisoning by these medicines and that physicians are aiding their
misuse. This agrees with a study in the UK [9], which reported that healthcare professionals are the
most common cause of the misuse of BZDs and Z-drugs due to their inappropriate prescribing practice.
Another significant problem is that approximately half of the prescriptions were not compliant
with the recommended maximum duration of treatment (4–5 weeks). This finding closely mirrors
previous research projects conducted by other researchers in the UK and Ireland, which report that
BZDs and Z-drugs are often prescribed for extended periods [9–12], which increases the risk of
dementia, especially with long-term use (more than three months) in elderly patients [30]. There is no
knowledge about outcomes in patients who receive BZDs or zolpidem at KFCH long-term, especially
regarding risks and side-effects.
The results of the present study showed that doctors did not review patients on long-term use
of BZDs or zolpidem, the only Z-drug available in the KSA, once they began using the medication;
this clarifies the continued prescription of these medicines for years by these physicians. This also
clarifies the likelihood of misuse of BZDs or Z-drugs by patients, or the development of dependency
or addiction to these drugs. It is possible, even probable, that most patients in the KSA are unaware of
the risks or side effects of such medicines. In fact, during data collection, we noticed that patients often
visited different clinics for the same medicine; these patients whose doctors fail to conduct a follow-up
are at high risk of dependence and drug–drug interactions [29]. For example, evidence suggests that
BZD use by patients with pulmonary disease might lead to respiratory depression [31]. Moreover,
drugs lose their sleep-inducing efficiency with prolonged use [31].
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This study had several strengths. To the best of our knowledge, this study is the first to explore the
treatment of insomnia in the KSA. More importantly, it provides researchers with baseline information
for further research. The study was also conducted in a major regional hospital (KFCH) in Jazan, one
of the many hospitals run by the MOH. We feel that KFCH in Jazan is representative of other major
hospitals of the MOH in the Kingdom. In other words, the practice identified here could be consistent
with other major hospitals of the MOH and, thus, the findings might be extrapolated to them.
One of the study’s limitations is its retrospective nature; older records were still being copied
by the Department of Medical Records from patients’ paper records at the time of the study, raising
the possibility that the study’s information might be incomplete. Despite this, the study may present
a reasonably accurate overview of current practice at KFCH. Another limitation is that it was conducted
in a single hospital in the KSA. Further work is therefore needed to determine practices nationwide.
5. Conclusions
The present study shows that physicians at KFCH do not comply with the guidelines developed
by the US [3,7] regarding the use of BZDs and Z-drugs to treat chronic, primary insomnia, and do
not document indications for their use; the latter requires clarification. A second issue is that the
non-pharmacological treatment form of insomnia (CBT-I) is not used in this major hospital. Therefore,
this study’s essential recommendations are that initial treatments for patients with primary insomnia
should be CBT-I and all physicians should be aware of its importance. Using non-pharmacological
treatment methods might ameliorate and/or prevent drug misuse. In any case, prescribing practices
related to the duration of treatment in the KSA do not conform to the US guidelines. To understand the
basis for this occurrence, further research on the factors that guide diagnostic and treatment practices
for insomnia in the Kingdom is required. Finally, the results show that patients using hypnotics
for the long-term were not reviewed by their doctors. It is important for patients to attend weekly
and monthly check-ups to ensure treatment process and the effects of medicines are determined in
a timely manner.
To overcome issues regarding the use of hypnotics in the KSA, the Saudi Ministry of Health
should review physicians’ practices and the availability of medicines on the Drug List; offer training to
prescribing physicians regarding best practice guidelines for managing insomnia; and introduce an
electronic care plan that prompts prescribers to consider CBT-I, choose the correct drug, dose, duration,
and review the patient’s medical history. The hospital’s computerized system should be improved
and physicians should be trained to use it. Saudi standards and guidelines for insomnia treatment
are required to govern the use and prescription of sleep medications. This will also help to provide
long-term optimal patient care.
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